The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this ...
Six weeks of neoadjuvant chemotherapy for patients with operable colon cancer is safe and results in downstaging, increased complete resection rates, and better disease control at 2 years, according ...
Investigators sought to identify factors and survival of patients with ovarian cancer after primary debulking surgery followed by adjuvant chemotherapy versus neo-adjuvant chemotherapy followed by int ...
A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made ...
Depending on the disease specifics, patients with melanoma may undergo pre- or post-surgical therapies. Skin melanoma, one of the most serious forms of skin cancer, poses a significant threat to ...
With a median follow-up of 14.7 months, event-free survival was significantly longer in the neoadjuvant-adjuvant therapy arm, with a hazard ratio of 0.58 when compared to the adjuvant therapy arm, ...
Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy. In this study, R, a bispecific checkpoint ...
Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...
Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, and potentially enhancing long-term disease control. Neoadjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results